Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

被引:83
|
作者
Poplawski, Sarah E. [1 ,2 ]
Lai, Jack H. [1 ,2 ]
Li, Youhua [1 ]
Jin, Zhiping [1 ]
Liu, Yuxin [1 ]
Wu, Wengen [1 ]
Wu, Yong [1 ]
Zhou, Yuhong [1 ]
Sudmeier, James L. [1 ]
Sanford, David G. [1 ,2 ]
Bachovchin, William W. [1 ,2 ]
机构
[1] Tufts Univ, Sackler Sch Biomed Sci, Dept Biochem, Boston, MA 02111 USA
[2] Arisaph Pharmaceut Inc, Boston, MA 02110 USA
关键词
DIPEPTIDYL PEPTIDASE IV; BORONIC ACID INHIBITORS; SERINE-PROTEASE; TUMOR-GROWTH; CLEAVING ENZYME; IN-VIVO; CELLS; ENDOPEPTIDASE; POLYPEPTIDE; DEGRADATION;
D O I
10.1021/jm400351a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for PAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-D-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.
引用
收藏
页码:3467 / 3477
页数:11
相关论文
共 50 条
  • [1] Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-? for different indications
    Plescia, Jessica
    Hedou, Damien
    Pousse, Maud Eva
    Labarre, Anne
    Dufresne, Caroline
    Mittermaier, Anthony
    Moitessier, Nicolas
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240
  • [2] Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein α
    Plescia, Jessica
    De Cesco, Stephane
    Patrascu, Mihai Burai
    Kurian, Jerry
    Di Trani, Justin
    Dufresne, Caroline
    Wahba, Alexander S.
    Janmamode, Naela
    Mittermaier, Anthony K.
    Moitessier, Nicolas
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7874 - 7884
  • [3] Suppression of Tumor Growth in Mice by Rationally Designed Pseudopeptide Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase
    Jackson, Kenneth W.
    Christiansen, Victoria J.
    Yadav, Vivek R.
    Silasi-Mansat, Robert
    Lupu, Florea
    Awasthi, Vibhudutta
    Zhang, Roy R.
    Mckee, Patrick A.
    NEOPLASIA, 2015, 17 (01): : 43 - 54
  • [4] Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP)
    Haffner, Curt D.
    Diaz, Caroline J.
    Miller, Aaron B.
    Reid, Robert A.
    Madauss, Kevin P.
    Hassell, Annie
    Hanlon, Mary H.
    Porter, David J. T.
    Becherer, J. David
    Carter, Luke H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (15) : 4360 - 4363
  • [5] Substituted 4-Carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibroblast Activation Protein
    Tsai, Ting-Yueh
    Yeh, Teng-Kuang
    Chen, Xin
    Hsu, Tsu
    Jao, Yu-Chen
    Huang, Chih-Hsiang
    Song, Jen-Shin
    Huang, Yu-Chen
    Chien, Chia-Hui
    Chiu, Jing-Huai
    Yen, Shih-Chieh
    Tang, Hung-Kuan
    Chao, Yu-Sheng
    Jiaang, Weir-Torn
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (18) : 6572 - 6583
  • [6] Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity
    Ryabtsova, Oxana
    Jansen, Koen
    Van Goethem, Sebastiaan
    Joossens, Jurgen
    Cheng, Jonathan D.
    Lambeir, Anne-Marie
    De Meester, Ingrid
    Augustyns, Koen
    Van der Veken, Pieter
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) : 3412 - 3417
  • [7] Targeting Inhibition of Fibroblast Activation Protein-α and Prolyl Oligopeptidase Activities on Cells Common to Metastatic Tumor Microenvironments
    Christiansen, Victoria J.
    Jackson, Kenneth W.
    Lee, Kyung N.
    Downs, Tamyra D.
    McKee, Patrick A.
    NEOPLASIA, 2013, 15 (04): : 348 - 358
  • [8] The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma
    Bracke, An
    Van Elzen, Roos
    Van der Veken, Pieter
    Augustyns, Koen
    De Meester, Ingrid
    Lambeir, Anne-Marie
    CLINICA CHIMICA ACTA, 2019, 495 : 154 - 160
  • [9] Isoquinoline alkaloids as prolyl oligopeptidase inhibitors
    Cahlikova, Lucie
    Hulova, Lucie
    Hrabinova, Martina
    Chlebek, Jakub
    Host'alkova, Anna
    Adamcova, Marketa
    Safratova, Marcela
    Jun, Daniel
    Opletal, Lubomir
    Locarek, Miroslav
    Macakova, Katerina
    FITOTERAPIA, 2015, 103 : 192 - 196
  • [10] Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α
    Jambunathan, Kalyani
    Watson, Douglas S.
    Endsley, Aaron N.
    Kodukula, Krishna
    Galande, Amit K.
    FEBS LETTERS, 2012, 586 (16) : 2507 - 2512